title: Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7-Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4-6: Unsplicing a Conflict.
authors.affiliation: Clinic of Urology, University Hospital Münster, Münster, Germany. Electronic address: julie.steinestel@ukmuenster.de.
authors.forename: Julie
authors.initials: J
authors.lastname: Steinestel
authors.affiliation: Clinic of Urology, University Hospital Münster, Münster, Germany.
authors.forename: Christof
authors.initials: C
authors.lastname: Bernemann
authors.affiliation: Clinic of Urology, University Hospital Münster, Münster, Germany.
authors.forename: Andres J
authors.initials: AJ
authors.lastname: Schrader
authors.affiliation: Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
authors.forename: Jochen K
authors.initials: JK
authors.lastname: Lennerz
mesh_terms: D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms
chemical_list: D017430:Prostate-Specific Antigen